keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy neuropathy

keyword
https://www.readbyqxmd.com/read/28729624/taxanes-and-platinum-derivatives-impair-schwann-cells-via-distinct-mechanisms
#1
Satoshi Imai, Madoka Koyanagi, Ziauddin Azimi, Yui Nakazato, Mayuna Matsumoto, Takashi Ogihara, Atsushi Yonezawa, Tomohiro Omura, Shunsaku Nakagawa, Shuji Wakatsuki, Toshiyuki Araki, Shuji Kaneko, Takayuki Nakagawa, Kazuo Matsubara
Impairment of peripheral neurons by anti-cancer agents, including taxanes and platinum derivatives, has been considered to be a major cause of chemotherapy-induced peripheral neuropathy (CIPN), however, the precise underlying mechanisms are not fully understood. Here, we examined the direct effects of anti-cancer agents on Schwann cells. Exposure of primary cultured rat Schwann cells to paclitaxel (0.01 μM), cisplatin (1 μM), or oxaliplatin (3 μM) for 48 h induced cytotoxicity and reduced myelin basic protein expression at concentrations lower than those required to induce neurotoxicity in cultured rat dorsal root ganglion (DRG) neurons...
July 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28729222/antiallodynic-effect-of-%C3%AE-caryophyllene-on-paclitaxel-induced-peripheral-neuropathy-in-mice
#2
Gabriela C Segat, Mariane N Manjavachi, Daiane O Matias, Giselle F Passos, Cristina Setim Freitas, Robson Costa, João B Calixto
Painful peripheral neuropathy is a common side effect of paclitaxel (PTX). The use of analgesics is an important component for management of PTX-induced peripheral neuropathy (PINP). However, currently employed analgesics have several side effects and are poorly effective. β-caryophyllene (BCP), a dietary selective CB2 agonist, has shown analgesic effect in neuropathic pain models, but its role in chemotherapy-induced neuropathic pain has not yet been investigated. Herein, we used the mouse model of PINP to show the therapeutic effects of BCP in this neuropathy...
July 17, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28726540/mechanisms-of-the-analgesic-effect-of-calcitonin-on-chronic-pain-by-alteration-of-receptor-or-channel-expression
#3
Akitoshi Ito, Megumu Yoshimura
The polypeptide hormone calcitonin is well known clinically for its ability to relieve osteoporotic back pain and neuropathic pain such as spinal canal stenosis, diabetic neuropathy, chemotherapy-induced neuropathy, and complex regional pain syndrome. Because the analgesic effects of calcitonin have a broad range, the underlying mechanisms of pain relief by calcitonin are largely unknown. However, recent studies using several types of chronic pain models combined with various methods have been gradually clarifying the mechanism...
January 2017: Molecular Pain
https://www.readbyqxmd.com/read/28726081/psoas-muscle-volume-as-a-predictor-of-peripheral-neurotoxicity-induced-by-primary-chemotherapy-in-ovarian-cancers
#4
Tomoyuki Yoshikawa, Masashi Takano, Morikazu Miyamoto, Isao Yajima, Yukihiro Shimizu, Yusuke Aizawa, Yuki Suguchi, Miki Moriiwa, Tadashi Aoyama, Hiroaki Soyama, Tomoko Goto, Junko Hirata, Ayako Suzuki, Hidenori Sasa, Isao Nagaoka, Hitoshi Tsuda, Kenichi Furuya
PURPOSE: Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The impact of sarcopenia on the treatment of ovarian cancers has not been determined. The present study aimed to evaluate correlation between sarcopenia and toxicities of chemotherapy in ovarian cancers. METHODS: Medical charts of the ovarian cancer patients that received chemotherapy with paclitaxel and carboplatin at our hospital between 2010 and 2015 were retrospectively reviewed...
July 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28722694/early-life-vincristine-exposure-evokes-mechanical-pain-hypersensitivity-in-the-developing-rat
#5
Katie A Schappacher, Lauren Styczynski, Mark L Baccei
Vincristine (VNC) is commonly used to treat pediatric cancers, including the most prevalent childhood malignancy, acute lymphoblastic leukemia. Although clinical evidence suggests that VNC causes peripheral neuropathy in children, the degree to which pediatric chemotherapeutic regimens influence pain sensitivity throughout life remains unclear, in part because of the lack of an established animal model of chemotherapy-induced neuropathic pain during early life. Therefore, this study investigated the effects of VNC exposure between postnatal days (P) 11 and 21 on mechanical and thermal pain sensitivity in the developing rat...
May 30, 2017: Pain
https://www.readbyqxmd.com/read/28712386/neuropeptide-y-improves-cisplatin-induced-bone-marrow-dysfunction-without-blocking-chemotherapeutic-efficacy-in-a-cancer-mouse-model
#6
Min Hee Park, In Kyung Jung, Woo-Kie Min, Jin Ho Choi, Gyu Man Kim, Hee Kyung Jin, Jae-Sung Bae
Cisplatin is the most effective and widely used chemotherapeutic agent for many types of cancer. Unfortunately, its clinical use is limited by its adverse effects, notably bone marrow suppression leading to abnormal hematopoiesis. We previously revealed that neuropeptide Y (NPY) is responsible for the maintenance of hematopoietic stem cell (HSC) function by protecting the sympathetic nervous system (SNS) fibers survival from chemotherapy-induced bone marrow impairment. Here, we show the NPY-mediated protective effect against bone marrow dysfunction due to cisplatin in an ovarian cancer mouse model...
July 17, 2017: BMB Reports
https://www.readbyqxmd.com/read/28711577/a-randomised-phase-ii-study-of-continuous-versus-stop-and-go-s-1-plus-oxaliplatin-following-disease-stabilisation-in-first-line-chemotherapy-in-patients-with-metastatic-gastric-cancer
#7
Sook Ryun Park, Mi-Jung Kim, Byung-Ho Nam, Chan Gyoo Kim, Jong Yeul Lee, Soo-Jeong Cho, Sun-Young Kong, Young-Iee Park
OBJECTIVES: We compared continuous versus stop-and-go chemotherapy after disease stabilisation with induction chemotherapy in the first-line treatment of metastatic gastric cancer (MGC). METHODS: MGC patients who achieved disease control after 6 cycles of S-1/oxaliplatin (SOX) were randomised to receive either continuous SOX until progression (continuous arm) or to have a chemotherapy-free interval followed by SOX reintroduction at progression (stop-and-go arm)...
July 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28708674/chemotherapy-induced-peripheral-neuropathy-a-review-of-recent-findings
#8
Peggy Y Kim, Carrie E Johnson
PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, frequently chronic condition characterized by pain and decreased function. Given the growing number of cancer survivors and an increasing recognition of opioid therapy limitations, there is a need for critical analysis of the literature in directing an informed and thoughtful approach for the management of painful CIPN. RECENT FINDINGS: A PubMed search for 'chemotherapy-induced peripheral neuropathy AND pain' identifies 259 publications between 1 January 2016 and 31 March 2017...
July 13, 2017: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/28702476/regulatable-transgene-expression-for-prevention-of-chemotherapy-induced-peripheral-neuropathy
#9
Daisuke Kawata, Zetang Wu
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating complication associated with drug treatment of cancer for which there are no effective strategies of prevention or treatment. In this study, we examined the effect of intermittent expression of neurotophin-3 (NT-3) or interleukin-10 (IL-10) from replication-defective herpes simplex virus (HSV)-based regulatable vectors delivered by subcutaneous inoculation to the dorsal root ganglion (DRG) on the development of paclitaxel-induced peripheral neuropathy...
September 15, 2017: Molecular Therapy. Methods & Clinical Development
https://www.readbyqxmd.com/read/28699105/tapentadol-in-neuropathic-pain-cancer-patients-a-prospective-open-label-study
#10
Edvina Galiè, Veronica Villani, Irene Terrenato, Andrea Pace
Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day...
July 11, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28698445/-a-case-of-albumin-bound-paclitaxel-induced-peripheral-neuropathy-without-exacerbation
#11
Masanobu Uchiyama, Toshitaka Goto, Miho Ueno, Hideki Kakimoto, Kouta Mashima, Yousuke Ikari, Yasushi Takamatsu, Kentaro Ogata, Hidetoshi Kamimura
Albumin-bound paclitaxel(nab-PTX)-associated neuropathy decreases the quality of life of cancer patients and leads to dose modification, discontinuation of chemotherapy, and occasionally dose-limiting toxicity. In the present case study, a 92- year-old female patient with peritoneal cancer of carcinomatous peritonitis and carcinomatous ascites was treated with carboplatin plus nab-PTX every 4 weeks as first-line chemotherapy, and a good response was achieved following 4 cycles of this regimen. However, the patient developed Grade 3 peripheral neuropathy and stopped the therapy...
June 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28697165/association-of-cyp3a5-expression-and-vincristine-neurotoxicity-in-pediatric-malignancies-in-turkish-population
#12
Hülya Kayilioğlu, Ulker Kocak, Derya Kan Karaer, Emriye F Percin, Ertan Sal, Funda Tekkesin, Melek Isik, Nergiz Oner, Fatma B Belen, Ebru Yilmaz Keskin, Arzu Okur, Meryem Albayrak, Zuhre Kaya, Faruk G Pinarli, Idil Yenicesu, Ceyda Karadeniz, Aynur Oguz, Turkiz Gursel
Vincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated...
July 10, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28695170/emotional-responses-to-persistent-chemotherapy-induced-peripheral-neuropathy-experienced-by-patients-with-colorectal-cancer-in-japan
#13
Kiyoko Kanda, Keiko Fujimoto, Ayumi Kyota
OBJECTIVE: For patients who wish to continue treatment for persistent chemotherapy-induced peripheral neuropathy (PCIPN) while maintaining the quality of life (QOL), the only effective way appears to be the stop-and-go strategy. The objective of the present study was to analyze emotional responses of Japanese patients with colorectal cancer (CRC) experiencing PCIPN for the first time and to consider effective ways of providing supportive nursing care. METHODS: In all, 25 patients with metastatic CRC who had completed more than six courses receiving first-line therapy with modified FOLFOX6 were included...
July 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28689961/pregabalin-reduces-cisplatin-induced-mechanical-allodynia-in-rats
#14
Yoshihiro Seto, Miyuki Takase, Yasuhiro Tsuji, Hideto To
Although cisplatin (CDDP) is a key drug in cancer chemotherapy, CDDP-induced peripheral neuropathy is a dose-limiting factor. We previously reported that CDDP-induced peripheral neuropathy, which progressed from allodynia to hypoalgesia, was ameliorated by the administration of CDDP to rats at a specific time. However, mechanical allodynia cannot be prevented therapeutically. Pregabalin (PGN) is used to suppress neuropathic pain from herpes zoster and diabetes. Therefore, we investigated the effects of PGN on CDDP-induced mechanical allodynia in rats...
June 20, 2017: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/28687964/predictors-of-the-usefulness-of-duloxetine-for-chemotherapy-induced-peripheral-neuropathy
#15
Yuko Kanbayashi, Megumi Inagaki, Hiroshi Ueno, Toyoshi Hosokawa
Duloxetine is an effective therapeutic agent for chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. Therefore, this retrospective study was performed to identify predictive factors of duloxetine response in CIPN patients to guide future strategies to improve the quality of life of patients undergoing chemotherapy. The participants were 74 cancer patients who were given duloxetine for relief of CIPN at our institute between October 2010 and January 2016...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28678741/role-of-nab-paclitaxel-in-metastatic-breast-cancer-a-meta-analysis-of-randomized-clinical-trials
#16
Yun Liu, Guoxin Ye, Dali Yan, Lei Zhang, Fan Fan, Jifeng Feng
Whether nab-paclitaxel and conventional taxanes are equally effective for metastatic breast cancer (MBC) remains unclear. We conducted meta-analysis of trials that compared nab-paclitaxel-based chemotherapy with solvent-based paclitaxel (sb-paclitaxel) and docetaxel-based chemotherapy. A literature search was performed to identify articles that compared nab-paclitaxel-based chemotherapy with sb-paclitaxel or docetaxel-based chemotherapy for MBC. Four randomized controlled trials (1,506 patients) were identified from 1,268 reports...
June 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28674258/roles-of-transient-receptor-potential-ankyrin-1-in-oxaliplatin-induced-peripheral-neuropathy
#17
Takayuki Nakagawa, Shuji Kaneko
Chemotherapy-induced peripheral neuropathy (CIPN), characterized by symptoms of paresthesia, dysesthesia, numbness, and pain, is a common adverse effect of several chemotherapeutic agents, including platinum-based agents, taxanes, and vinca alkaloids. However, no effective prevention or treatment strategies exist for CIPN because the mechanisms underpinning this neuropathy are poorly understood. Recent accumulating evidence suggests that some transient receptor potential (TRP) channels functioning as nociceptors in primary sensory neurons are responsible for CIPN...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28670077/mixed-phenotypic-acute-leukemia-with-leukemia-cutis-and-neuroleukemiosis
#18
Rona Joseph Poikayil, Geetha Narayanan, Harish Sugathan, Lali V Soman
Leukemia cutis and neuroleukemiosis are two rare extramedullary manifestations of acute leukemia. We report a 32-year-old woman with multiple skin lesions and painful peripheral neuropathy. Bone marrow biopsy and skin biopsy confirmed the diagnosis of mixed phenotypic acute leukemia. After induction chemotherapy, she attained marrow remission, her skin lesion resolved completely, and her neurologic symptoms significantly improved.
July 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28668863/phase-i-study-of-neoadjuvant-chemotherapy-with-capecitabine-and-oxaliplatin-for-locally-advanced-gastric-cancer
#19
Hironaga Satake, Masato Kondo, Motoko Mizumoto, Takeshi Kotake, Yoshihiro Okita, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Akira Miki, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
AIM: To determine the recommended dose of neoadjuvant chemotherapy of combined capecitabine and oxalipatin (G-XELOX) for locally advanced gastric cancer. PATIENTS AND METHODS: Patients received two cycles of neoadjuvant chemotherapy with oxaliplatin on day 1 and capecitabine (2,000 mg/m(2)/day, b.i.d.) on days 1-14, repeated every 3 weeks. They then underwent gastrectomy with curative D2/3 lymph-node dissection followed by adjuvant therapy with S-1 for 1 year. De-escalation of oxaliplatin dose was planned (starting at level 1, oxalipatin 130 mg/m(2))...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668762/mangafodipir-a-selective-cytoprotectant-with-special-reference-to-oxaliplatin-and-its-association-to-chemotherapy-induced-peripheral-neuropathy-cipn
#20
REVIEW
Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised because of severe toxicity. Chemotherapy-induced peripheral neuropathy (CIPN) is the most problematic dose-limiting toxicity of oxaliplatin. Oncologists included for years calcium and magnesium infusion as part of clinical practice for preventing CIPN. Results from a phase III prospective study published in 2014, however, overturned this practice...
June 29, 2017: Translational Oncology
keyword
keyword
70500
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"